BR0214845A - Sìntese de 4,5-diidro-pirazol[3,4-c]pirid-2-onas - Google Patents

Sìntese de 4,5-diidro-pirazol[3,4-c]pirid-2-onas

Info

Publication number
BR0214845A
BR0214845A BR0214845-5A BR0214845A BR0214845A BR 0214845 A BR0214845 A BR 0214845A BR 0214845 A BR0214845 A BR 0214845A BR 0214845 A BR0214845 A BR 0214845A
Authority
BR
Brazil
Prior art keywords
dihydro
pyrid
pyrazolo
ones
synthesis
Prior art date
Application number
BR0214845-5A
Other languages
English (en)
Inventor
Jiacheng Zhou
Lynette M Oh
Philip Ma
Huy-Yin Li
Pasquale N Confalone
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of BR0214845A publication Critical patent/BR0214845A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
    • C07D211/86—Oxygen atoms
    • C07D211/88—Oxygen atoms attached in positions 2 and 6, e.g. glutarimide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
    • C07D211/86—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

"SìNTESE DE 4,5-DIIDRO-PIRAZOL[3,4-C[PIRID-2-ONAS". São descritos um novo processo e intermediários do mesmo para fabricação de 4,5-diidro-pirazol[3,4-c]pirid-2onas do tipo mostrado a seguir a partir de fenil hidrazinas apropriadas. Estes compostos são úteis como inibidores de fator Xa.
BR0214845-5A 2001-12-10 2002-12-03 Sìntese de 4,5-diidro-pirazol[3,4-c]pirid-2-onas BR0214845A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33908501P 2001-12-10 2001-12-10
PCT/US2002/038559 WO2003049681A2 (en) 2001-12-10 2002-12-03 Synthesis of 4,5-dihydro-pyrazolo [3,4-c] pyrid-2-ones

Publications (1)

Publication Number Publication Date
BR0214845A true BR0214845A (pt) 2004-12-07

Family

ID=23327425

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0214845-5A BR0214845A (pt) 2001-12-10 2002-12-03 Sìntese de 4,5-diidro-pirazol[3,4-c]pirid-2-onas

Country Status (13)

Country Link
US (3) US6919451B2 (pt)
EP (1) EP1467984A4 (pt)
JP (1) JP2005511712A (pt)
KR (1) KR20040073467A (pt)
CN (1) CN1639147A (pt)
AU (1) AU2002346624A1 (pt)
BR (1) BR0214845A (pt)
HU (1) HUP0500109A3 (pt)
IL (1) IL161955A0 (pt)
MX (1) MXPA04005508A (pt)
PL (1) PL371930A1 (pt)
TW (2) TW200738672A (pt)
WO (1) WO2003049681A2 (pt)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI331526B (en) 2001-09-21 2010-10-11 Bristol Myers Squibb Pharma Co Lactam-containing compounds and derivatives thereof as factor xa inhibitors
ATE544750T1 (de) * 2001-09-21 2012-02-15 Bristol Myers Squibb Co Lactamhaltige verbindungen und ihre derivate als faktor-xa-hemmer
US20070203178A1 (en) * 2004-09-28 2007-08-30 Malley Mary F Crystalline solvates of apixaban
US7396932B2 (en) * 2004-09-28 2008-07-08 Bristol-Myers Squibb Company Process for preparing 4,5-dihydro-pyrazolo[3,4-c]pyrid-2-ones
US20060069085A1 (en) * 2004-09-28 2006-03-30 Rulin Zhao Preparation of 4,5-dihydro-pyrazolo[3,4-c]pyrid-2-ones
CN101065379B (zh) * 2004-09-28 2011-05-11 布里斯托尔-迈尔斯斯奎布公司 制备4,5-二氢-吡唑并[3,4-c]吡啶-2-酮的方法
US7304157B2 (en) 2004-09-28 2007-12-04 Bristol-Myers Squibb Company Efficient synthesis of 4,5-dihydro-pyrazolo[3,4-c]pyrid-2-ones
DE102006025315A1 (de) * 2006-05-31 2007-12-06 Bayer Healthcare Ag Tetrahydro-pyrrolopyridin-, Tetrahydro-pyrazolopyridin-, Tetrahydro-imidazopyridin- und Tetrahydro-triazolopyridin-Derivate und ihre Verwendung
DE102007028406A1 (de) 2007-06-20 2008-12-24 Bayer Healthcare Ag Substituierte Oxazolidinone und ihre Verwendung
DE102007028319A1 (de) 2007-06-20 2008-12-24 Bayer Healthcare Ag Substituierte Oxazolidinone und ihre Verwendung
DE102007028407A1 (de) 2007-06-20 2008-12-24 Bayer Healthcare Ag Substituierte Oxazolidinone und ihre Verwendung
DE102007032344A1 (de) * 2007-07-11 2009-01-15 Bayer Healthcare Ag Prodrug-Derivate von 1-(4-Methoxyphenyl)-7-oxo-6-[4-(2-oxopiperidin-1-yl)phenyl]-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridin-3-carboxamid
US20090076069A1 (en) * 2007-09-14 2009-03-19 Protia, Llc Deuterium-enriched apixaban
US20100130543A1 (en) * 2008-09-15 2010-05-27 Auspex Pharmaceuticals, Inc. Pyrazole carboxamide inhibitors of factor xa
CN101967145B (zh) * 2010-09-09 2012-07-04 华东理工大学 一种抗血栓药物阿匹沙班的制备方法
ITMI20111047A1 (it) * 2011-06-10 2012-12-11 Dipharma Francis Srl Forma cristallina di apixaban
ITMI20111135A1 (it) * 2011-06-22 2012-12-23 Dipharma Francis Srl Procedimento per la preparazione di apixaban
US8884016B2 (en) 2011-06-10 2014-11-11 Dipharma Francis S.R.L. Apixaban preparation process
CN103242310A (zh) * 2012-02-10 2013-08-14 苏州迈泰生物技术有限公司 吡唑并吡啶酮类化合物及其在制备抗凝血药物中的用途
CN102675314A (zh) * 2012-06-14 2012-09-19 南京正科制药有限公司 一种阿哌沙班的合成方法
CN103626759B (zh) * 2012-08-24 2015-10-21 上海医药工业研究院 一种阿哌沙班的中间体的制备方法
WO2014072884A1 (en) * 2012-11-12 2014-05-15 Alembic Pharmaceuticals Limited Process for the synthesis of apixaban
CZ304846B6 (cs) 2012-11-13 2014-12-03 Zentiva, K.S. Způsob přípravy APIXABANU
EP2945946B1 (en) 2013-01-17 2017-07-12 Glenmark Pharmaceuticals Limited Process for the preparation and purification of apixaban
CN103539795A (zh) * 2013-03-18 2014-01-29 齐鲁制药有限公司 阿哌沙班的多晶型及其制备方法
CN104109165A (zh) * 2013-04-19 2014-10-22 四川海思科制药有限公司 4,5-二氢-吡唑并[3,4-c]吡啶-2-酮衍生物、其制备方法以及应用
CZ2013305A3 (cs) 2013-04-23 2014-11-05 Zentiva, K.S. Nové krystalické formy APIXABANU a způsob jejich přípravy
WO2014203275A2 (en) 2013-06-18 2014-12-24 Cadila Healthcare Limited An improved process for the preparation of apixaban and intermediates thereof
CN103739541B (zh) * 2014-01-07 2016-01-20 上海现代制药股份有限公司 5,6-二氢-3-(4-吗啉基)-1-[4-(2-氧代-1-哌啶基)苯基]-2(1h)-吡啶酮的制备方法
IN2014MU00197A (pt) 2014-01-21 2015-08-28 Wanbury Ltd
CN103896940B (zh) * 2014-03-25 2016-02-03 江苏弘和药物研发有限公司 一种阿哌沙班的合成方法
CN103923080B (zh) * 2014-04-04 2016-06-22 苏州景泓生物技术有限公司 一种制备抗血栓药物阿哌沙班的方法
CN104045637B (zh) * 2014-04-18 2016-04-06 河北科技大学 一种阿哌沙班的制备方法
WO2015162551A1 (en) 2014-04-21 2015-10-29 Mylan Laboratories Ltd Process for the preparation of apixaban
KR102412045B1 (ko) * 2014-05-22 2022-06-22 놀스 차이나 파마수티칼 컴퍼니., 엘티디. 혈액응고인자 Xa 억제제로서의 히드라지드 화합물
WO2015177801A1 (en) * 2014-05-23 2015-11-26 Symed Labs Limited Novel process for the preparation of a lactam-containing compound
HU231122B1 (hu) 2014-08-06 2020-11-30 Egis Gyógyszergyár Zrt Eljárás apixaban előállítására
DK3180335T3 (da) 2014-08-11 2021-08-09 Angion Biomedica Corp Cytokrom-p450-inhibitorer og anvendelser deraf
CN104311555B (zh) * 2014-09-19 2016-04-20 广东东阳光药业有限公司 吡唑并哌啶酮类化合物及其组合物及用途
CN104327074B (zh) * 2014-09-19 2016-01-06 广东东阳光药业有限公司 含有内酰胺取代基的吡唑并哌啶酮类化合物及其组合物及用途
CN104311558B (zh) * 2014-09-19 2016-06-01 广东东阳光药业有限公司 含有环己烷取代基的吡唑并哌啶酮类化合物及其组合物及用途
CN104277037B (zh) * 2014-09-19 2015-12-09 广东东阳光药业有限公司 含有螺环的吡唑并哌啶酮类化合物及其组合物及用途
CN104277040B (zh) * 2014-09-19 2016-04-20 广东东阳光药业有限公司 含有酰基哌嗪酮取代基的吡唑并哌啶酮类化合物及其组合物及用途
EP3009435B1 (en) * 2014-10-15 2016-08-17 F.I.S.- Fabbrica Italiana Sintetici S.p.A. Apixaban glycol esters as key intermediates and impurities of the synthesis of Apixaban
WO2016067308A1 (en) 2014-10-28 2016-05-06 Jubilant Generics Limited (Formerly Jubilant Life Sciences Division) Process for the preparation of apixaban and intermediates thereof
HU230991B1 (hu) * 2014-11-19 2019-08-28 Egis Gyógyszergyár Zrt. Eljárás és köztitermék apixaban előállítására
US9603846B2 (en) 2014-11-25 2017-03-28 Cadila Healthcare Limited Process for the preparation of apixaban
WO2016109492A1 (en) 2014-12-31 2016-07-07 Angion Biomedica Corp Methods and agents for treating disease
CN104892601B (zh) * 2015-06-09 2017-09-19 江苏中邦制药有限公司 一种抗血栓药物阿哌沙班的制备方法
EP3064497A1 (en) * 2015-07-20 2016-09-07 F.I.S.- Fabbrica Italiana Sintetici S.p.A. Dimer impurities of apixaban and method to remove them
CN106632312B (zh) * 2015-11-03 2019-05-14 上海医药工业研究院 一种阿哌沙班有关物质、中间体、制备方法及其应用
CN105732618A (zh) * 2016-02-02 2016-07-06 扬州大学 一种合成4-(2-氧代哌啶-1-基)芳基羧酸乙酯类化合物的方法
ES2827459T3 (es) * 2016-04-04 2021-05-21 Zakl Farmaceutyczne Polpharma Sa Procedimiento para la preparación de apixaban
US10077263B2 (en) * 2016-04-29 2018-09-18 Optimus Drugs Private Limited Process for the preparation of Apixaban
CN106117200B (zh) * 2016-06-27 2018-02-02 张士伟 预防或治疗关节置换静脉血栓药物阿哌沙班的制备方法
WO2018049214A1 (en) 2016-09-09 2018-03-15 Incyte Corporation Pyrazolopyridine derivatives as hpk1 modulators and uses thereof for the treatment of cancer
US20180072741A1 (en) 2016-09-09 2018-03-15 Incyte Corporation Pyrazolopyrimidine compounds and uses thereof
CN115819417A (zh) 2016-09-09 2023-03-21 因赛特公司 作为hpk1调节剂的吡唑并吡啶衍生物及其用于治疗癌症的用途
CN107434806A (zh) * 2016-12-09 2017-12-05 陕西科技大学 一种阿哌沙班羧酸衍生物的γ晶型固体物质及其制备方法与用途
US20180228786A1 (en) 2017-02-15 2018-08-16 Incyte Corporation Pyrazolopyridine compounds and uses thereof
US10722495B2 (en) 2017-09-08 2020-07-28 Incyte Corporation Cyanoindazole compounds and uses thereof
CN107955002B (zh) * 2017-12-27 2019-12-24 上海博志研新药物技术有限公司 阿哌沙班及其中间体的制备方法
CN107955003A (zh) * 2017-12-28 2018-04-24 河北常山生化药业股份有限公司 一种阿哌沙班中间体2合成过程中特定杂质s4的清除方法
CN107936015B (zh) * 2017-12-28 2020-05-12 浙江天宇药业股份有限公司 一种n-1晶型的阿哌沙班的合成方法
US10745388B2 (en) 2018-02-20 2020-08-18 Incyte Corporation Indazole compounds and uses thereof
WO2019164847A1 (en) 2018-02-20 2019-08-29 Incyte Corporation Indazole compounds and uses thereof
PL3755703T3 (pl) 2018-02-20 2022-11-07 Incyte Corporation Pochodne n-(fenylo)-2-(fenylo)pirymidyno-4-karboksyamidu i związki pokrewne jako inhibitory hpk1 do leczenia nowotworu
US11299473B2 (en) 2018-04-13 2022-04-12 Incyte Corporation Benzimidazole and indole compounds and uses thereof
US10899755B2 (en) 2018-08-08 2021-01-26 Incyte Corporation Benzothiazole compounds and uses thereof
EP3856348B1 (en) 2018-09-25 2024-01-03 Incyte Corporation Pyrazolo[4,3-d]pyrimidine compounds as alk2 and/or fgfr modulators
KR102188341B1 (ko) 2018-10-24 2020-12-08 하나제약 주식회사 아픽사반의 제조방법
AU2020326703A1 (en) 2019-08-06 2022-02-17 Incyte Corporation Solid forms of an HPK1 inhibitor
CN111253392B (zh) * 2019-12-17 2021-06-11 哈尔滨珍宝制药有限公司 一种制备阿哌沙班的方法
CN113214142B (zh) * 2020-01-21 2024-01-30 浙江九洲药业股份有限公司 一种阿哌沙班的中间体及制备方法
JP2022022550A (ja) * 2020-06-26 2022-02-07 ダイト株式会社 アピキサバンの新規製造方法
CN112142736B (zh) * 2020-10-29 2021-08-10 怀化学院 一种阿哌沙班杂质1的制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2459240A1 (fr) 1979-06-21 1981-01-09 Cm Ind Aminopiperidines anorexigenes, procede pour leur preparation, intermediaires dans ledit procede et medicaments qui les contiennent
CN100340559C (zh) 1998-12-23 2007-10-03 布里斯托尔-迈尔斯斯奎布药品公司 作为凝血因子xa抑制剂的含氮杂双环
US6329527B1 (en) 1999-10-21 2001-12-11 Bristol-Myers Squibb Pharma Company Synthesis of 1,3,5-trisubstituted pyrazoles
TWI331526B (en) 2001-09-21 2010-10-11 Bristol Myers Squibb Pharma Co Lactam-containing compounds and derivatives thereof as factor xa inhibitors
ATE544750T1 (de) * 2001-09-21 2012-02-15 Bristol Myers Squibb Co Lactamhaltige verbindungen und ihre derivate als faktor-xa-hemmer
US7304157B2 (en) * 2004-09-28 2007-12-04 Bristol-Myers Squibb Company Efficient synthesis of 4,5-dihydro-pyrazolo[3,4-c]pyrid-2-ones
US7396932B2 (en) * 2004-09-28 2008-07-08 Bristol-Myers Squibb Company Process for preparing 4,5-dihydro-pyrazolo[3,4-c]pyrid-2-ones
US20060069085A1 (en) * 2004-09-28 2006-03-30 Rulin Zhao Preparation of 4,5-dihydro-pyrazolo[3,4-c]pyrid-2-ones

Also Published As

Publication number Publication date
EP1467984A2 (en) 2004-10-20
US20030181466A1 (en) 2003-09-25
TW200738672A (en) 2007-10-16
IL161955A0 (en) 2005-11-20
JP2005511712A (ja) 2005-04-28
KR20040073467A (ko) 2004-08-19
HUP0500109A3 (en) 2007-08-28
TW200303201A (en) 2003-09-01
HUP0500109A2 (hu) 2005-05-30
WO2003049681A2 (en) 2003-06-19
EP1467984A4 (en) 2005-12-07
US7153960B2 (en) 2006-12-26
MXPA04005508A (es) 2004-12-06
WO2003049681A3 (en) 2003-09-18
US6919451B2 (en) 2005-07-19
PL371930A1 (en) 2005-07-11
US20070027186A1 (en) 2007-02-01
AU2002346624A1 (en) 2003-06-23
CN1639147A (zh) 2005-07-13
US20050245566A1 (en) 2005-11-03

Similar Documents

Publication Publication Date Title
BR0214845A (pt) Sìntese de 4,5-diidro-pirazol[3,4-c]pirid-2-onas
BRPI0516187A (pt) processo para preparação de [3, 4-c]pirid-2-onas de 4, 5-diidro-pirazolo
PL369740A1 (en) Novel dihydropteridinones, method for producing the same and the use thereof as medicaments
WO2006135425A3 (en) Preparation of 4,5-dihydro-pyrazolo[3,4-c]pyrid-2-ones
BR0307432A (pt) Difluormetiltiazolilcarboxanilidas
ATE452882T1 (de) Herstellung von quetiapin
HK1088013A1 (en) Pyrimidine compounds having phosphonate groups as antiviral nucleotide analogs
BR0202518A (pt) Método para produção de uma composição, composição, e, método para aderir um material a um substrato
BRPI0516172A (pt) processo para a preparação de 4,5-diidro-pirazol[3,4-c]pirid-2-onas
DE50208918D1 (de) 6-aminomorphinanderivate, herstellungsverfahren dafür und deren verwendung
BR0312863A (pt) Derivados de aldeìdo de polietileno glicol
NO20040388L (no) Fremgangsmåte for fremstilling av beraprost og salter derav, samt forbindelser som er mellomprodukter i fremgangsmåten
DE602004023786D1 (de) Herstellung von hochreinem Alkylgallium
ATE353884T1 (de) Multifunktionelle kationische photoinitiatoren, deren herstellung und verwendung
NO20016151L (no) Fremstilling av substituerte piperidin-4-oner
RS20060206A (en) Aminopyridine-derivatives as inducible no-synthase inhibitors
BR0214445B1 (pt) processos para a produção de compostos.
DE60323748D1 (de) 1,3-diaza-dibenzoazulene als inhibitoren der produfür deren herstellung
DE69808922D1 (de) Thiazolobenzoheterocyclen, ihre herstellung und diese enthaltende phatrmazeutische zubereitungen
NO20031046D0 (no) Fremgangsmåte for fremstilling av en substituert imidazopyridinforbindelse
PT1250335E (pt) Processo e intermediarios para a preparacao de imidazopiridinas
NO20052392L (no) Fremgangsmate for fremstilling av acetylenforbindelser.
WO2005054175A3 (en) New process for the preparation of nitrooxyderivatives of paracetamol
WO2004096828A3 (fr) Nouveau procede et intermediaires de preparation de composes 19-nor-steroïdes
BR0315508A (pt) Processo para preparação de compostos de pirazol

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2108 DE 31/05/2011.